References in periodicals archive ?
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
Bausch + Lomb said on Friday that it has achieved the primary endpoints in the first Phase 3, multi-centre, double-masked, vehicle-controlled, parallel-group study of its next generation sub-micron gel formulation of loteprednol etabonate.
US-based Kala Pharmaceuticals has commenced Phase II clinical trial (KPI-121-C-004) of its loteprednol etabonate MPP (LE-MPP) drug product, KP-121, in patients with intraretinal or subretinal fluid secondary to retinal vein occlusion (RVO) or diabetic macular oedema (DME), it was reported on Friday.
M2 PHARMA-August 4, 2014-Kala Pharmaceuticals starts Phase II clinical trial of loteprednol etabonate MPP
6) Indeed, the steroid loteprednol etabonate has been shown to be significantly more effective in treating the signs and symptoms of CLGPC compared to a placebo in several randomised controlled trials.
Pharmaceuticals sales increased 17 percent in the second quarter, led by the Company's lines of prescription drugs containing loteprednol etabonate (Lotemax([R]), Alrex([R]) and Zylet([R]) ophthalmic drops), combined with higher sales of ocular vitamins, drug delivery implants and over-the-counter general eye care products, including the recently acquired Alaway([TM]) product line for relieving itchy eyes associated with allergies.
United States-based Kala Pharmaceuticals has started two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) programme, KPI-121, it was reported on Friday.
05% (Durezol) every hour and loteprednol etabonate 0.
3% ophthalmic suspension), combining the proven anti-inflammatory power of loteprednol etabonate with the broad-spectrum anti-infective agent tobramycin; and Alrex([R] )(loteprednol etabonate ophthalmic suspension 0.
The steroid loteprednol etabonate has also demonstrated efficacy in treating the signs and symptoms of CLGPC in several randomised controlled trials.
Pharmaceuticals sales growth reflected continued gains in prescriptions for the Company's proprietary eye drops containing loteprednol etabonate and higher sales of ocular vitamins.